TY - JOUR
T1 - Are higher doses of nicotine replacement more effective for smoking cessation?
AU - Hughes, John R.
AU - Lesmes, George R.
AU - Hatsukami, Dorothy K.
AU - Richmond, Robyn L.
AU - Lichtenstein, Edward
AU - Jorenby, Douglas E.
AU - Broughton, Joseph O.
AU - Fortmann, Stephen P.
AU - Leischow, Scott J.
AU - McKenna, James P.
AU - Rennard, Stephen I.
AU - Wadland, William C.
AU - Heatley, Scott A.
N1 - Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 1999/6
Y1 - 1999/6
N2 - This study determined whether higher dose nicotine patches are more efficacious than lower dose patches among heavy smokers. A randomized double-blind study compared 0, 21, 35, and 42 ing/day of a 24-h patch in 1039 smokers (≥30 cigarettes/day) at 12 clinical sites in the USA and one in Australia. Daily patches were used for 6 weeks followed by tapering over the next 10 weeks. Weekly group therapy occurred. Biochemically validated self-reported quit rates at 6, 12, 26, and 52 weeks post-cessation were measured. Quit rates were dose-related at all follow-ups (p < 0.01). Continuous, biochemically verified abstinence rates for the 0, 21, 35, and 42 mg doses at the end of treatment (12 weeks) were 16, 24, 30, and 39%. At 6 months, the rates were 13, 20, 20, and 26%. Among the 11 sites with 12 month follow-up (n = 879), the quit rates were 7, 13, 9, and 19%. In post-hoc tests, none of the active doses were significantly different from each other at any follow-up. The rates of dropouts due to adverse events for 0, 21, 35, and 42 mg were 3, 1, 3, and 6% (p = n.s.). Our results are similar to most prior smaller studies; i.e., in heavy smokers higher doses increase quit rates slightly. Longer durations of treatment may be necessary to show greater advantages from higher doses.
AB - This study determined whether higher dose nicotine patches are more efficacious than lower dose patches among heavy smokers. A randomized double-blind study compared 0, 21, 35, and 42 ing/day of a 24-h patch in 1039 smokers (≥30 cigarettes/day) at 12 clinical sites in the USA and one in Australia. Daily patches were used for 6 weeks followed by tapering over the next 10 weeks. Weekly group therapy occurred. Biochemically validated self-reported quit rates at 6, 12, 26, and 52 weeks post-cessation were measured. Quit rates were dose-related at all follow-ups (p < 0.01). Continuous, biochemically verified abstinence rates for the 0, 21, 35, and 42 mg doses at the end of treatment (12 weeks) were 16, 24, 30, and 39%. At 6 months, the rates were 13, 20, 20, and 26%. Among the 11 sites with 12 month follow-up (n = 879), the quit rates were 7, 13, 9, and 19%. In post-hoc tests, none of the active doses were significantly different from each other at any follow-up. The rates of dropouts due to adverse events for 0, 21, 35, and 42 mg were 3, 1, 3, and 6% (p = n.s.). Our results are similar to most prior smaller studies; i.e., in heavy smokers higher doses increase quit rates slightly. Longer durations of treatment may be necessary to show greater advantages from higher doses.
UR - http://www.scopus.com/inward/record.url?scp=0033139420&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033139420&partnerID=8YFLogxK
U2 - 10.1080/14622299050011281
DO - 10.1080/14622299050011281
M3 - Article
C2 - 11072398
AN - SCOPUS:0033139420
SN - 1462-2203
VL - 1
SP - 169
EP - 174
JO - Nicotine and Tobacco Research
JF - Nicotine and Tobacco Research
IS - 2
ER -